ASC Theraputics Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • ASC Theraputics's estimated annual revenue is currently $4.3M per year.(i)
  • ASC Theraputics's estimated revenue per employee is $155,000

Employee Data

  • ASC Theraputics has 28 Employees.(i)
  • ASC Theraputics grew their employee count by -10% last year.

ASC Theraputics's People

NameTitleEmail/Phone
1
Chief Medical OfficerReveal Email/Phone
2
VP Gene and Cell TherapyReveal Email/Phone
3
SVP, Global OperationsReveal Email/Phone
4
VP, Global Regulatory AffairsReveal Email/Phone
5
Senior Director QualityReveal Email/Phone
6
Senior Director, CMC Head, Cell and Gene TherapyReveal Email/Phone
7
Scientist and Senior Lab ManagerReveal Email/Phone
8
Executive Assistant and HR ManagerReveal Email/Phone
9
Principle ScientistReveal Email/Phone
10
Senior ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is ASC Theraputics?

ASC Therapeutics focuses on the development of curative therapies for rare diseases. Our gene, CRISPR and cell therapies were developed at Applied StemCell, a life sciences company for over 12 years, including proprietary gene editing technologies. Our development pipeline includes several preclinical stage projects focusing on monogenic blood disorders that exhibit a high genetic penetrance and conditions requiring immunomodulatory interventions. Contact us for partnership opportunities. #therapeutics #CRISPR #celltherapy #genetherapy #blooddisorders #hemophilia www.asctherapeutics.com

keywords:N/A

N/A

Total Funding

28

Number of Employees

$4.3M

Revenue (est)

-10%

Employee Growth %

N/A

Valuation

N/A

Accelerator

ASC Theraputics News

2022-04-17 - World Hemophilia Day: Exploring the Latest R&D Breakthroughs

Most recently, ASC Therapeutics received Fast Track Designation from the U.S. Food and Drug Administration for its therapy for hemophilia A,...

2022-03-30 - ASC Therapeutics Receives Key Regulatory Designations in ...

ASC Therapeutics is a biopharmaceutical company pioneering the development of gene replacement therapies, in-vivo gene editing and allogeneic...

2022-03-30 - Global Hemophilia A Pipeline Insights | Clinical Trials ...

... include Spark Therapeutics, Sigilon Therapeutics, ASC Therapeutics, ... Essential Hemophilia A Pipeline therapies such as SPK-8011,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5.4M28-10%N/A
#2
$5.3M2812%N/A
#3
$6.5M28-10%N/A
#4
$4.8M2812%N/A
#5
$4.3M28-18%N/A